Valence8 US’s Insmed INSM Stock Holding History

Valence8 US’s Portfolio INSM Stock Details INSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-6,600	Closed	-$482K	–	34
2024 Q3	$482K	Buy	+6,600	New	+$487K	0.2%	23

Other funds holding INSM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Valence8 US's INSM Position: Q4 2024 in Review

Valence8 US sold out of Insmed (INSM) in Q4 2024, closing a stake of 7,865 shares — an estimated $574K sold.

Valence8 US first reported a position in INSM in Q3 2024 and held it in 1 quarter. The position peaked at $574K in Q3 2024. 438 funds tracked by Wall St. Rank hold INSM as of Q4 2024.

Valence8 US reported no remaining Insmed position as of Q4 2024 after selling out during the quarter.
Valence8 US sold 7,865 Insmed shares in Q4 2024, an estimated $574K.
Valence8 US first reported a position in Insmed in Q3 2024 and held it in 1 quarter.
Valence8 US's Insmed position peaked at $574K in Q3 2024.
438 funds tracked by Wall St. Rank held Insmed as of Q4 2024.

Based on Valence8 US's 13F filing for Q4 2024, filed 12 Feb 2025.